Sequencing BCMA Myeloma Therapies

Sequencing BCMA Myeloma Therapies

Symposium | How to sequence CAR T-cell therapy and bispecific antibodies in R/R multiple myelomaПодробнее

Symposium | How to sequence CAR T-cell therapy and bispecific antibodies in R/R multiple myeloma

Unanswered questions regarding the sequencing of BCMA-targeting agents in multiple myelomaПодробнее

Unanswered questions regarding the sequencing of BCMA-targeting agents in multiple myeloma

For a triple-class refractory patient entering 4L therapy, how to sequence BCMA/GPRC5D bispecifics?Подробнее

For a triple-class refractory patient entering 4L therapy, how to sequence BCMA/GPRC5D bispecifics?

Sequencing of BCMA-directed therapies for multiple myelomaПодробнее

Sequencing of BCMA-directed therapies for multiple myeloma

Hitting the BCMA Target in Multiple MyelomaПодробнее

Hitting the BCMA Target in Multiple Myeloma

The sequencing of novel therapies in myeloma (CAR-T, bispecifics, antibody-drug conjugates)Подробнее

The sequencing of novel therapies in myeloma (CAR-T, bispecifics, antibody-drug conjugates)

For a triple-class refractory patient entering 4L therapy, how to sequence BCMA/GPRC5D bispecifics?Подробнее

For a triple-class refractory patient entering 4L therapy, how to sequence BCMA/GPRC5D bispecifics?

Optimal sequencing of immunotherapies to improve outcomes for patients with multiple myelomaПодробнее

Optimal sequencing of immunotherapies to improve outcomes for patients with multiple myeloma

Moving BCMA-targeted agents to the frontline setting in myeloma & sequencing immunotherapiesПодробнее

Moving BCMA-targeted agents to the frontline setting in myeloma & sequencing immunotherapies

Sequencing BCMA-targeted agents in multiple myelomaПодробнее

Sequencing BCMA-targeted agents in multiple myeloma

Translating Data: Post-BCMA TherapyПодробнее

Translating Data: Post-BCMA Therapy

Potential Sequencing of BCMA-Directed Therapies in RRMMПодробнее

Potential Sequencing of BCMA-Directed Therapies in RRMM

Selecting and Utilizing Anti-BCMA Therapy in Relapsed and Refractory Multiple MyelomaПодробнее

Selecting and Utilizing Anti-BCMA Therapy in Relapsed and Refractory Multiple Myeloma

Sequencing BCMA-targeted therapies in myelomaПодробнее

Sequencing BCMA-targeted therapies in myeloma

Multiple Myeloma Precursor Conditions | Overview | Therapeutic InterventionПодробнее

Multiple Myeloma Precursor Conditions | Overview | Therapeutic Intervention

Determining the optimal sequencing of anti-BCMA therapies in multiple myelomaПодробнее

Determining the optimal sequencing of anti-BCMA therapies in multiple myeloma

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MD